- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05727553
Implementation of Online Adaptive Radiotherapy for Breast Cancer Patients on Ethos (BREAST-ART) (BREAST-ART)
February 21, 2023 updated by: H.J.G.D. van den Bongard, Amsterdam UMC, location VUmc
Implementation of Online Adaptive Radiotherapy for Breast Cancer Patients on Ethos
Postoperative radiotherapy is for the majority of breast cancer patients the standard of care.
During postoperative radiotherapy, unexpected dosimetric deviations can occur due to breast contour changes resulting from resorption of postoperative breast or chest wall seroma/hematoma, oedema either postoperatively or during irradiation, or arm/body positioning variation.
In approximately 10% of cases, repositioning after setup imaging is not sufficient, and offline plan adaptation is required.
When a new treatment planning is required in the standard offline workflow this will take in general 2 days.
By using an online adaptive workflow with a daily treatment planning this delay and extra work caused by offline plan adaptation can be omitted.
The aim of this study is to translate the offline adaptive workflow to an online adaptive workflow, and investigate the experiences of patients who have been treated with online adaptive radiotherapy for breast cancer (BREAST-ART).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
In this single-arm prospective BREAST-ART study breast cancer patients with an indication for postoperative radiotherapy will be treated according to the Dutch and institutional guidelines.
Target volumes will be the whole breast, chest wall, axillary levels, tumor bed boost and partial breast irradiation on the right side and left side with a deep inspiration breath hold technique.
Robust templates are developed for offline and online treatment planning with an IMRT tangential multiple-beam setup.
A simulation of the online adaptive workflow is performed in breast cancer patients already treated on the Ethos-linac with the standard offline adaptive workflow.
Patients will be treated following the online adaptive workflow delivered on the Ethos-Linac.
Patient experience will be evaluated using an in-house developed questionnaires after the first and last fraction, scoring treatment satisfaction on a 4-point Likert scale.
Furthermore, all dosimetric data, volume details, DICOM images and the time spend on all parts of the online adaptive workflow will be evaluated.
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Noord Holland
-
Amsterdam, Noord Holland, Netherlands, 1081 HV
- Recruiting
- Amsterdam UMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Breast cancer patients undergoing postoperative radiation treatment.
Description
Inclusion Criteria:
- Breast cancer patients referred for postoperative radiotherapy of the breast, chest wall, axillary levels, tumor bed boost or partial breast irradiation.
- Age of 18 years and older.
- Adequate understanding and communicating the Dutch language.
- Written informed consent for use of routinely collected clinical data and to fill out questionnaires.
Exclusion Criteria:
- Patients not suitable for postoperative radiotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breast cancer patients
Breast cancer patients treated with postoperative radiotherapy in an online adaptive workflow on Ethos.
|
Postoperative radiotherapy will be indicated conform the standard medical care and guidelines.
The radiation is delivered with online adaptive radiotherapy performed on the Ethos.
This technique will be evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time spend on the online adaptive workflow
Time Frame: 30 minutes
|
All separate parts of the online adaptive workflow will be registered in minutes, starting when the patients enters the room of the radiation machine until the patient leaves the room.
|
30 minutes
|
|
Patient experience
Time Frame: 10 minutes
|
Patient experience is measured using an in-house designed short study questionnaire after the first and the last radiation fraction.
The questionnaires is on a 4-point Likert scale with a lowest score for discomfort and the highest score appears for good comfort.
|
10 minutes
|
|
Dosimetric data
Time Frame: 1 week
|
The dosimetric data of the standard offline treatment plan (reference plan), scheduled plan and the online adapted treatment plan (adapted plan) will be compared.
|
1 week
|
|
DICOM images
Time Frame: 1 week
|
DICOM images of the standard offline treatment plan (reference plan), scheduled plan and the online adapted treatment plan (adapted plan) will be compared.
|
1 week
|
|
Volumes
Time Frame: 1 week
|
Target volumes of clinical target volume (CTV), planning target volume (PTV), coverage of CTV and PTV will be registred in cubic centimetres.
|
1 week
|
|
Number of monitor units (MU).
Time Frame: 1 week
|
The number of monitor units (MU) will be compared between the reference treatment plan, scheduled plan and adapted treatment plan.
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiation associated toxicity
Time Frame: Baseline, 1 month and 3 months after radiotherapy
|
Toxicity will be assessed by the Common Terminology Criteria Adverse Events version 5.0.
|
Baseline, 1 month and 3 months after radiotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 10, 2021
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
March 1, 2024
Study Registration Dates
First Submitted
December 13, 2022
First Submitted That Met QC Criteria
February 3, 2023
First Posted (Actual)
February 14, 2023
Study Record Updates
Last Update Posted (Estimate)
February 23, 2023
Last Update Submitted That Met QC Criteria
February 21, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00002991
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on Online adaptive radiotherapy
-
Peking Union Medical College HospitalTongji Hospital; Zhongnan Hospital; Jingzhou First People's Hospital; The First... and other collaboratorsRecruiting
-
Peking Union Medical College HospitalActive, not recruitingEndometrial Neoplasms | Uterine Cervical NeoplasmChina
-
Peking Union Medical College HospitalCompletedEndometrial Neoplasms | Uterine Cervical NeoplasmChina
-
Peking Union Medical College HospitalActive, not recruitingUterine Cervical NeoplasmChina
-
Rigshospitalet, DenmarkRecruitingHead & Neck Squamous Cell CarcinomaDenmark
-
Herlev HospitalRecruitingAnal Squamous Cell Carcinoma | Anal Cancer | Anal CarcinomaDenmark
-
University of AarhusOdense University Hospital; Copenhagen University Hospital at HerlevCompletedAdverse Effects for Adaptive RT of Bladder CancerDenmark
-
Haukeland University HospitalRecruiting
-
University Hospital, EssenRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Adaptive Radiotherapy | OptimizationGermany
-
M.D. Anderson Cancer CenterTerminated